XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) is a publicly traded Healthcare sector company. As of May 21, 2026, XTLB trades at $2.52 with a market cap of $6.39M and a P/E ratio of 0.00. XTLB moved -2.57% today. Year to date, XTLB is +1.34%; over the trailing twelve months it is -43.64%. Its 52-week range spans $2.12 to $10.28. Rallies surfaces XTLB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in XTLB news today?
XTL Biopharmaceuticals to Issue 40% Equity and Raise $1.5M to Acquire Psyga’s GMP Psilocybin Platform: XTL Biopharmaceuticals will acquire 100% of Psyga Bio through issuing ADSs representing 40% of its share capital plus a $1.5M private placement, with up to 10% additional equity tied to clinical and commercialization milestones. Psyga’s GMP-ready facility supports botanical and synthetic psilocybin production and seven approved Phase 2a trials.
EDELMAN JOSEPH sold 9.60M (~$1.47M) on Nov 19, 2008.
EDELMAN JOSEPH sold 24.68M (~$3.48M) on Nov 18, 2008.
EDELMAN JOSEPH sold 2.70M (~$412.02K) on Nov 18, 2008.
XTLB Analyst Consensus
XTLB analyst coverage data. Average price target: $0.00.
Common questions about XTLB
What changed in XTLB news today?
XTL Biopharmaceuticals to Issue 40% Equity and Raise $1.5M to Acquire Psyga’s GMP Psilocybin Platform: XTL Biopharmaceuticals will acquire 100% of Psyga Bio through issuing ADSs representing 40% of its share capital plus a $1.5M private placement, with up to 10% additional equity tied to clinical and commercialization milestones. Psyga’s GMP-ready facility supports botanical and synthetic psilocybin production and seven approved Phase 2a trials.
Does Rallies summarize XTLB news?
Yes. Rallies summarizes XTLB news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is XTLB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for XTLB. It does not provide personalized investment advice.
